Veracyte (VCYT) AI Stock Analysis

• Market Cap: $3.36B
• Dividend Yield: N/A
• Average Volume (3M): 783.87K
• Price to Earnings (P/E): 111.9
• Beta (1Y): 1.19
• Revenue Growth: 16.41%
• EPS Growth: N/A
• Country: US
• Employees: 824
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): 0.51
• Shares Outstanding: 79,049,170
• 10 Day Avg. Volume: 707,400
• 30 Day Avg. Volume: 783,865
• PEG Ratio: -0.96
• Price to Book (P/B): 2.58
• Price to Sales (P/S): 6.79
• P/FCF Ratio: 47.47
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 4.87
• Enterprise Value/Gross Profit: 7.14
• Enterprise Value/Ebitda: 51.15
• 1Y Price Target: $42.17
• Price Target Upside: 16.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: $53.00 ▲(46.73% Upside)

Veracyte's strong financial performance and positive earnings call are the most significant factors driving the score. The company shows robust revenue growth and profitability, supported by strategic initiatives. However, the high P/E ratio suggests potential overvaluation, and technical indicators show strong momentum but caution due to overbought signals.

Veracyte Business Overview & Revenue Model

Company Description

Veracyte, Inc. (VCYT) is a genomic diagnostics company focused on improving patient outcomes through accurate and timely disease diagnosis. The company specializes in providing innovative diagnostic solutions primarily in the fields of oncology and pulmonary medicine. Veracyte's core products include its flagship Afirma genomic sequencing classifier for thyroid cancer diagnosis, as well as other tests designed to enhance the detection and management of cancer and other diseases, leveraging advanced genomic technologies.

How the Company Makes Money

Veracyte generates revenue primarily through the sale of its diagnostic tests to healthcare providers, which include hospitals, clinics, and laboratories. The company charges fees for each test performed, which are typically covered by insurance providers, thus facilitating access for patients. Additionally, Veracyte may engage in partnerships with pharmaceutical companies or research institutions that can contribute to revenue through collaborative research agreements or co-development of new tests. The company may also receive royalties or licensing fees from their intellectual property related to their diagnostic technologies.

Veracyte Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Veracyte Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 36.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCYT, the sentiment is Neutral. The current price of 36.12 is below the 20-day moving average (MA) of 44.07, below the 50-day MA of 41.33, and above the 200-day MA of 32.47, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 48.13 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VCYT.

Veracyte Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
VCYT	76 Outperform	$3.36B	111.90	2.49%	―	16.41%	―
ARQT	60 Neutral	$3.55B	-81.72	-28.17%	―	129.21%	80.35%
TVTX	56 Neutral	$3.55B	-36.55	-410.78%	―	114.22%	77.02%
IMVT	45 Neutral	$5.27B	-9.25	-95.93%	―	―	-27.70%
CELC	44 Neutral	$4.73B	-27.85	-122.04%	―	―	-40.75%
IRON	43 Neutral	$3.03B	-14.99	-34.78%	―	―	-34.96%

Veracyte Corporate Events

Veracyte Inc. Reports Robust Q3 Earnings Performance

Veracyte Inc. recently held its earnings call, revealing a strong quarter marked by record revenue growth and profitability. The company showcased robust performance from its core testing business, particularly Decipher and Afirma, achieving a significant milestone by reaching its adjusted EBITDA margin target ahead of schedule. Despite these achievements, challenges remain, including declining biopharmaceutical revenue, competitive pressures from new technologies, and a slight decrease in testing ASP.

Veracyte Reports Strong Q3 2025 Financial Performance

Veracyte, Inc., a prominent player in the cancer diagnostics industry, specializes in providing high-value genomic tests that aid clinicians in diagnosing and treating cancer effectively. In its latest earnings report for the third quarter of 2025, Veracyte announced a significant increase in both total and testing revenues, with the latter reaching $127.8 million, marking a 17% rise year-over-year. The company also reported a net income of $19.1 million, reflecting a 26% improvement from the previous year, and an adjusted EBITDA of $39.7 million, showcasing a 45% growth.

Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones

Veracyte’s latest earnings call exuded a positive sentiment, marked by robust revenue and volume growth, alongside significant strategic milestones. The company showcased promising future product launches, despite facing some financial challenges such as a decline in product revenue and increased operating expenses. However, these challenges were overshadowed by the positive highlights, setting a hopeful tone for the company’s future.

Veracyte Reports Strong Q2 2025 Revenue Growth

Veracyte, Inc., a prominent player in the cancer diagnostics sector, is dedicated to enhancing cancer care through its innovative genomic tests and bioinformatic capabilities. In its latest earnings report for the second quarter of 2025, Veracyte reported a 14% increase in total revenue, reaching $130.2 million, driven by strong performance in its Decipher and Afirma tests. The company also recorded a significant increase in testing volume, with Decipher achieving a 28% growth. Despite a GAAP net loss of $1.0 million due to a $20.5 million impairment charge, Veracyte’s adjusted EBITDA improved by 49% year-over-year to $35.8 million. The company’s strategic focus on expanding its Decipher test for metastatic cancer patients and the successful restructuring of its French subsidiary are key highlights. Looking ahead, Veracyte has raised its full-year revenue guidance, reflecting confidence in sustained growth, supported by its robust platform and expanding clinical evidence base.